Chloramphenicol Is a Potent Inhibitor of Cytochrome P450 Isoforms CYP2C19 and CYP3A4 in Human Liver Microsomes

Chiaro Young Park,* Kyoung-Ah Kim, and Su-Lyun Kim

Department of Pharmacology, Gachon Medical School, Incheon, Korea

Received 2 June 2003/Returned for modification 3 July 2003/Accepted 12 August 2003

The inhibitory effect of chloramphenicol on human cytochrome P450 (CYP) isoforms was evaluated with human liver microsomes and cDNA-expressed CYPs. Chloramphenicol had a potent inhibitory effect on CYP2C19-catalyzed S-mephenytoin 4′-hydroxylation and CYP3A4-catalyzed midazolam 1-hydroxylation, with apparent 50% inhibitory concentrations (inhibitory constant [K_i] values are shown in parentheses) of 32.0 (7.7) and 48.1 (10.6) μM, respectively. Chloramphenicol also weakly inhibited CYP2D6, with an apparent 50% inhibitory concentration (K_i) of 375.9 (75.8) μM. The mechanism of the drug interaction reported between chloramphenicol and phenytoin, which results in the elevation of plasma phenytoin concentrations, is clinically assumed to result from the inhibition of CYP2C9 by chloramphenicol. However, using human liver microsomes and cDNA-expressed CYPs, we showed this interaction arises from the inhibition of CYP2C19- not CYP2C9-catalyzed phenytoin metabolism. In conclusion, inhibition of CYP2C19 and CYP3A4 is the probable mechanism by which chloramphenicol decreases the clearance of coadministered drugs, which manifests as a drug interaction with chloramphenicol.

Chloramphenicol, a broad-spectrum antibiotic, has been used to treat severe infections for several decades. Its use in contemporary medical practice has fallen out of favor due to dose-dependent and idiosyncratic bone marrow suppression (9). However, chloramphenicol showed good in vitro activity against many vancomycin-resistant enterococcal infections and is useful for certain life-threatening infections (22, 30).

Chloramphenicol increased the plasma drug concentrations or effects of several drugs, such as cyclosporine, tacrolimus, and phenytoin (4, 10, 14, 17, 20, 25, 29, 32, 36, 38).

Cytochrome P450s (CYPs) play a key role in the oxidation of numerous endogenous and exogenous compounds (24, 38). In previous animal studies, in vivo treatment with chloramphenicol has been shown to inhibit CYP-catalyzed reactions in microsomal preparations in rats, suggesting that the drug interactions of chloramphenicol possibly involve the CYPs (2, 8, 15).

However, there are no published studies investigating the effect of chloramphenicol on different CYP isoforms in human liver microsomes. Therefore, we studied the inhibitory effect of chloramphenicol on the activities of the major CYP isoforms in human liver microsomes and cDNA-expressed CYPs, using selective marker reactions to clarify the mechanism underlying the drug-drug interactions of chloramphenicol.

**MATERIALS AND METHODS**

**Materials.** Chloramphenicol, phenytoin, S-(5-hydroxyphenyl)-5-phenylhydantoin (HPHP), phenacetin, acetaminophen, chloroxazone, paclitaxel, dextromethorphan, dextrophan, furafylline, NADP, EDTA, MgCl_2, glucose-6-phosphate (G-6-P), and G-6-P dehydrogenase (G-6-PDH) were purchased from Sigma-Aldrich (St. Louis, Mo.). 1-Hydroxymidazolam, S-warfarin, 7-hydroxywarfarin, S-mephenytoin, 6-hydroxypaclitaxel, and 4′-hydroxymephenytoin were obtained from Ultrafine Chemical Co. (Manchester, United Kingdom). Acetonitrile and methanol were acquired from Fisher Scientific Co. (Pittsburgh, Pa.). Midazolam was kindly provided by Bukwang Pharmaceutical Co. (Seoul, Korea). All other reagents and chemicals used were of analytical or high-performance liquid chromatography (HPLC) grade. Human liver microsomes containing specific content of CYPs from donors (HG-43, HG-56, and HG-89) were obtained from Gentest Corp. (Woburn, Mass.). Human CYPs were recombinant CYPs (1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4) were also purchased from Gentest Corp.

**Enzyme assay studies.** All incubations were performed in duplicate, and the mean values were used. We measured the activities of CYP1A2, CYP2C9, CYP2C19, CYP2D6, CY3A4, and CYP3A4 by using specific reaction probe drugs. The K_m and V_max values were determined in human liver microsomes for the CYP isoform-specific reactions used, for which the incubation conditions and method references are listed in Table 1.

We used the free base form of chloramphenicol, which is microbiologically active. A 25 mM chloramphenicol stock solution was prepared by dissolving chloramphenicol in distilled water, and this solution was serially diluted in distilled water. The reaction metabolite of the probe drug for each CYP was quantified by interpolating the peak area ratios of the respective metabolite and the internal standard from a standard curve of known metabolite concentrations.

Each incubation was performed with cDNA-expressed CYPs or human liver microsomes in a final incubation volume of 0.25 ml, after they were diluted from their original stock concentrations (final concentrations, 0.25 to 1 mg/ml for microsomes and 20 to 40 pmol/liter for cDNA-expressed CYPs). The incubation medium contained 100 mM phosphate buffer (pH 7.4) containing an NADPH-generating system (HPLC grade). Human liver microsomes containing specific content of CYPs from donors (HG-43, HG-56, and HG-89) were obtained from Gentest Corp. (Woburn, Mass.). Human CYPs were recombinant CYPs (1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4) were also purchased from Gentest Corp.

**Enzyme assay studies.** All incubations were performed in duplicate, and the mean values were used. We measured the activities of CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CY3A4, and CYP3A4 by using specific reaction probe drugs. The K_m and V_max values were determined in human liver microsomes for the CYP isoform-specific reactions used, for which the incubation conditions and method references are listed in Table 1.

We used the free base form of chloramphenicol, which is microbiologically active. A 25 mM chloramphenicol stock solution was prepared by dissolving chloramphenicol in distilled water, and this solution was serially diluted in distilled water. The reaction metabolite of the probe drug for each CYP was quantified by interpolating the peak area ratios of the respective metabolite and the internal standard from a standard curve of known metabolite concentrations.

Each incubation was performed with cDNA-expressed CYPs or human liver microsomes in a final incubation volume of 0.25 ml, after they were diluted from their original stock concentrations (final concentrations, 0.25 to 1 mg/ml for microsomes and 20 to 40 pmol/liter for cDNA-expressed CYPs). The incubation medium contained 100 mM phosphate buffer (pH 7.4) containing an NADPH-generating system (including 1.3 mM NADP, 3.3 mM G-6-P, 3.3 mM MgCl_2, and 1.0 U of G-6-PDH per ml). For each substrate (probe drug), preliminary experiments were performed to determine whether metabolite formation was linear with respect to incubation time and microsomal protein concentrations. After incubation at 37°C with the probe drug and microsomes in the absence (control) and presence of the NADPH-generating system, reactions were stopped by placing the reactants on ice and adding the appropriate stop solution (described in the corresponding reference in Table 1). CYP2C19-catalyzed S-mephenytoin 4′-hydroxylation was a modification of the reaction described by Ko et al. (13). After S-mephenytoin (25 to 100 μM) was incubated with human liver microsomes (1 mg/ml) for 30 min at 37°C in the presence of the NADPH-generating system, the reaction was stopped by placing it on ice and adding 70 μl of perchloric acid. Carbamazepine was added as the internal standard. The mixture was centrifuged at 10,000 × g for 5 min at 4°C, and aliquots of the supernatant were injected onto an HPLC system (Lichrosorb RP18 [4.6 by 250 mm]; UV, 225 nm; 320:680 acetonitrile–1% acetic acid [pH 4.0] at 0.7 ml/min). CYP3A4-catalyzed midazolam 1-hydroxylation was performed by a modifica-
TABLE 1. CYP isoform-specific probe drug reactions

<table>
<thead>
<tr>
<th>CYP</th>
<th>Index reaction</th>
<th>Final microsomal conc (mg/ml)</th>
<th>Incubation time (min)</th>
<th>$K_i$ (μM)</th>
<th>$V_{max}$ (pmol/min/mg protein)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP1A2</td>
<td>Phenacetin O-deethylation</td>
<td>2</td>
<td>25</td>
<td>35</td>
<td>879</td>
<td>27</td>
</tr>
<tr>
<td>CYP2C9</td>
<td>S-Warfarin 7-hydroxylation</td>
<td>0.25</td>
<td>15</td>
<td>9.7</td>
<td>14.5</td>
<td>41</td>
</tr>
<tr>
<td>CYP2C19</td>
<td>S-Mephenytoin 4'-hydroxylation</td>
<td>1</td>
<td>30</td>
<td>87</td>
<td>295</td>
<td>13</td>
</tr>
<tr>
<td>CYP2D6</td>
<td>Dextromethorphan O-demethylation</td>
<td>0.5</td>
<td>30</td>
<td>11</td>
<td>255</td>
<td>1</td>
</tr>
<tr>
<td>CYP2C8</td>
<td>Paclitaxel 6α-hydroxylation</td>
<td>1</td>
<td>20</td>
<td>25</td>
<td>400</td>
<td>40</td>
</tr>
<tr>
<td>CYP3A4</td>
<td>Midazolam 1-hydroxylation</td>
<td>0.25</td>
<td>5</td>
<td>12</td>
<td>550</td>
<td>23</td>
</tr>
<tr>
<td>CYP2E1</td>
<td>Chlormezanone 6-hydroxylation</td>
<td>0.4</td>
<td>25</td>
<td>85</td>
<td>960</td>
<td>19</td>
</tr>
</tbody>
</table>

$V_{max}$, the maximum velocity of metabolite formation.

$K_i$, Michaelis-Menten constant.

RESULTS

Inhibitory effect of chloramphenicol on CYP-catalyzed reactions. Chloramphenicol strongly inhibited CYP2C19-catalyzed S-mephenytoin 4'-hydroxylation and CYP3A4-catalyzed midazolam 1-hydroxylation in human liver microsomes, with apparent $IC_{50}$ of 32.0 and 48.1 μM, respectively (Fig. 1). The Lineweaver-Burk plot, Dixon plots, and secondary reciprocal plots indicated that chloramphenicol inhibited CYP2C19 activity with a mixed-type inhibition pattern, with an apparent $K_i$ value of 7.7 μM (Fig. 2 and Table 2). In the case of the CYP3A4-catalyzed reaction, chloramphenicol exhibited competitive inhibition with an apparent $K_i$ value of 10.6 μM (Fig. 3 and Table 2). Chloramphenicol also showed competitive and moderate inhibition of the CYP2D6-catalyzed reaction with an $IC_{50}$ ($K_i$) of 375.9 (75.8) μM, but did not inhibit or only minimally inhibited the other CYP-catalyzed reactions tested (Fig. 1). To evaluate whether chloramphenicol acts as a mechanism-based inhibitor of CYP-catalyzed reactions, we preincubated chloramphenicol with NADPH for 15 min prior to the addition of the CYP-specific substrates, but this did not increase the degree of inhibition (data not shown).

The mechanism of chloramphenicol-induced inhibition of phenytoin metabolism. The inhibitory effect of chloramphen-
that the drug interaction between phenytoin and chloramphenicol involves the inhibition of CYP2C19 (Fig. 4).

**DISCUSSION**

Studies using rats or mice have shown that chloramphenicol is an inhibitor of CYP in liver microsomes (2, 24, 26). It has therefore been presumed a priori that chloramphenicol is an inhibitor of CYPs in humans. Furthermore, several drug interactions between chloramphenicol and coadministered drugs have supported this hypothesis (4, 10, 14, 17, 20, 25, 29, 32, 36). However, little has been known of the inhibitory effect of chloramphenicol on human CYPs until now. In the present study, we confirmed that chloramphenicol has an inhibitory effect on CYP2C19, CYP3A4, and, to a lesser extent, CYP2D6 in human liver microsomes.

Chloramphenicol has been suggested to be effective in the treatment of vancomycin-resistant enterococcal infections in transplantation patients (22, 30). Calcineurin inhibitors, including cyclosporine and tacrolimus, interact with chloramphenicol when used in a combination therapy, causing an increase in their plasma drug concentrations and/or their toxicity (4, 20, 32, 36). Because both tacrolimus and cyclosporine are metabolized via CYP3A4 (16, 31, 37), the results of the present study indicate that the inhibition of CYP3A4-catalyzed reactions by chloramphenicol is the underlying mechanism by which the concentrations of both cyclosporine and tacrolimus in plasma are elevated by the administration of chloramphenicol.

In contrast, chloramphenicol is purported to be a CYP2C9 inhibitor, because chloramphenicol interacts with several drugs, such as phenytoin, warfarin, and phenobarbital (10, 14, 17, 25, 28, 38), which are mainly metabolized via CYP2C9 (7, 18, 21, 41). Interestingly, we observed no inhibitory effect of chloramphenicol on CYP2C9 in human liver microsomal preparations.

The CYP2C subfamily is the second-most-abundant CYP protein in the human liver following CYP3A (30%), representing about 20% of the total CYPs (34). CYP2C9 is clearly the most abundant CYP2C protein expressed, followed by CYP2C19 and CYP2C8 (28). Among the CYP2C isoforms tested, chloramphenicol only inhibited CYP2C19-catalyzed reaction. Phenytoin is metabolized by CYP2C9 and, to a lesser extent, by CYP2C19 (3, 7, 18, 35). Although CYP2C9 is mainly responsible for phenytoin metabolism, several drugs, such as tricyclic antidepressants, ticlopidine, omeprazole, and cimetidine, also influence concentrations of phenytoin in plasma through the inhibition of CYP2C19, but not through CYP2C9 inhibition (5, 6, 11). In the present study, chloramphenicol selectively inhibited CYP2C19-catalyzed reaction and not

**FIG. 2.** (A) Representative Dixon plot for the inhibition by chloramphenicol (0 to 100 μM) of CYP2C19-catalyzed S-mephenytoin 4′-hydroxylation in human liver microsomes with 25 (●), 50 (○), 75 (▲), or 100 (△) μM S-mephenytoin. (B) Lineweaver-Burk plot of CYP2C19-catalyzed S-mephenytoin 4′-hydroxylation in the absence (■) or presence of 10 (▲), 20 (●), 50 (○), or 100 (△) μM chloramphenicol. (C) Secondary plot of slopes taken from Lineweaver-Burk plots versus chloramphenicol concentration. Each data point represents the average of duplicate measurements.

**TABLE 2.** Inhibition of CYP2C19, CYP2D6, and CYP3A4 isoforms by chloramphenicol and predicted in vivo inhibition of the metabolism of coadministered CYP2C19, CYP2D6, and CYP3A4 substrates by chloramphenicol, respectively, from in vitro data

<table>
<thead>
<tr>
<th>CYP isoform</th>
<th>IC_{50} (K) (μM)</th>
<th>Type of inhibition</th>
<th>Predicted in vivo inhibition (\frac{I((1+K_i))}{K_{i}})</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP2C19</td>
<td>32.0 (7.7)</td>
<td>Mixed (α = 4.2)</td>
<td>0.62-0.80</td>
</tr>
<tr>
<td>CYP2D6</td>
<td>375.9 (75.8)</td>
<td>Competitive</td>
<td>0.14-0.29</td>
</tr>
<tr>
<td>CYP3A4</td>
<td>48.1 (10.6)</td>
<td>Competitive</td>
<td>0.54-0.74</td>
</tr>
</tbody>
</table>

*IC_{50} values are derived from secondary plots of slopes taken from double-reciprocal plots versus chloramphenicol concentrations, and the IC_{50}s were calculated graphically.

The inhibitor concentration (I) of chloramphenicol (therapeutic concentrations, 10 to 25 μg/ml [31 to 77 μM] and the fraction of drug unbound to protein are about 40% (see Discussion for details).
CYP2C9 in microsomal preparations. Furthermore, only CYP2C19-catalyzed phenytoin p-hydroxylation was inhibited by chloramphenicol. Taken together, these results indicate that chloramphenicol is an inhibitor of CYP2C19, and not of CYP2C9.

We found several reports of drug interactions between chloramphenicol and warfarin, but chloramphenicol did not inhibit S-warfarin 7-hydroxylation catalyzed by CYP2C9 in the present study. However, we cannot rule out the possibility that another isof orm of warfarin (R-warfarin) interacts with chloramphenicol, because warfarin is a chiral drug composed of S and R forms (11). S-Warfarin is metabolized by CYP2C9, whereas R-warfarin is metabolized mainly by CYP1A2 and CYP3A4 (7, 11). Moreover, when we incubated a racemate of warfarin with chloramphenicol in human liver microsomes, we found chloramphenicol inhibited R-warfarin metabolism, whereas S-warfarin was not inhibited (data not shown). We have also found numerous case reports of interactions between warfarin and CYP3A4 inhibitors (12, 33, 42). Taken together,
these data suggest that CYP3A4 inhibition by chloramphenicol may be the mechanism underlying the inhibition of warfarin metabolism, especially the inhibition of R-warfarin.

Theoretically, drug interactions based on the inhibition of hepatic metabolism, $i$, can be predicted by both the $K_i$ value and the concentration of the inhibitor, $[I]$, around the metabolic enzyme in the liver by using the following predictive model: $i = [I]/(K_i + [I])$, assuming that the substrate concentration is much lower than its $K_m$ value (39). Based on the hypothesis that only the unbound forms of a drug in plasma are available for diffusion to intrahepatic regions of metabolic activity, the unbound concentration of an inhibitor in plasma has been used to predict in vivo drug interactions. Considering that therapeutic concentrations of chloramphenicol in plasma are 31 to 77 μmol/liter and protein binding is around 60%, we would expect approximately 54 to 80% inhibition of the clearance of CYP3A4 and CYP2C19 substrates by chloramphenicol (Table 2), suggesting that chloramphenicol is a potent inhibitor of CYP3A4 and CYP2C19 in vivo. Even though CYP2D6 was not potently inhibited by chloramphenicol, it also showed a 14 to 29% inhibition of clearance, suggesting that circumstances such as hypoalbuminemia and elevated concentrations of chloramphenicol in plasma are 31 to 77 μmol/liter and protein binding is around 60%.}

In conclusion, our in vitro study demonstrates that chloramphenicol by chloramphenicol may explain the mechanism of the interactions between chloramphenicol and coadministered drugs.

REFERENCES